Evidence map›Paper›PMID 33441653›Full record

ArticleScientific reports2021

Quantitative STAU2 measurement in lymphocytes for breast cancer risk assessment.

Charoenchai Puttipanyalears, Sikrit Denariyakoon, Phonthep Angsuwatcharakon, Vitavat Aksornkitti, Mawin Vongsaisuwan, Sutasinee Asayut, Somchai Thanasitthichai, Narisorn Kongruttanachok, Chatchawit Aporntewan, Apiwat Mutirangura

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Charoenchai PuttipanyalearsCenter of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand.
Sikrit DenariyakoonThe Queen Sirikit Center for Breast Cancer, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, 10330, Thailand.
Phonthep AngsuwatcharakonCenter of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand.
Vitavat AksornkittiCenter of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand.
Mawin VongsaisuwanDepartment of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Sutasinee AsayutResearch and Technology Assessment Department, National Cancer Institute, Bangkok, 10400, Thailand.
Somchai ThanasitthichaiResearch and Technology Assessment Department, National Cancer Institute, Bangkok, 10400, Thailand.
Narisorn KongruttanachokDepartment of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Chatchawit AporntewanCenter of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand.
Apiwat MutiranguraCenter of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand. mapiwat@chula.ac.th.
Chulalongkorn University · THNational Cancer Institute of Thailand · THThai Red Cross Society · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although mammograms play a key role in early breast cancer detection, the test is not applicable to all women, for example, women under the age of 40. The development of a noninvasive blood test with high sensitivity and accessibility will improve the effectiveness of breast cancer screening programmes. Secretory factors released from cancer cells can induce the expression of certain genes in a large number of white blood cells (WBCs). Therefore, cancer-dependent proteins in WBCs can be used as tumour markers with high sensitivity. Five proteins (LMAN1, AZI2, STAU2, MMP9 and PLOD1) from a systemic analysis of a variety of array data of breast cancer patients were subjected to immunofluorescence staining to evaluate the presence of fixed WBCs on 96-well plates from 363 healthy females and 358 female breast cancer patients. The results revealed that the average fluorescence intensity of anti-STAU2 and the percentage of STAU2-positive T and B lymphocytes in breast cancer patients (110.50 ± 23.38 and 61.87 ± 12.44, respectively) were significantly increased compared with those in healthy females (56.47 ± 32.03 and 33.02 ± 18.10, respectively) (p = 3.56 × 10

Indexed as

AdultBiomarkers, TumorBreast NeoplasmsFemaleHeLa CellsHumansLymphocytesMiddle AgedNerve Tissue ProteinsNeuronsRisk AssessmentRisk FactorsRNA-Binding ProteinsRNA, MessengerBiomarkers, TumorNerve Tissue ProteinsRNA-Binding ProteinsRNA, MessengerSTAU2 protein, human

Identifiers

PMID33441653
PMCPMC7806934
OpenAlexW3120079042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.